Athira Pharma downgraded by Rodman & Renshaw
$ATHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 → $0.50 | Outperform → Neutral | Mizuho |
| 9/4/2024 | Buy → Neutral | Rodman & Renshaw | |
| 9/4/2024 | Buy → Neutral | BTIG Research | |
| 9/4/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/19/2024 | $22.00 | Buy | Rodman & Renshaw |
| 10/17/2022 | $20.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 7/7/2022 | $6.00 | Buy | Mizuho |
| 6/23/2022 | $36.00 → $5.00 | Buy → Hold | Stifel |
4/A - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
10-Q - Athira Pharma, Inc. (0001620463) (Filer)
8-K - Athira Pharma, Inc. (0001620463) (Filer)
EFFECT - Athira Pharma, Inc. (0001620463) (Filer)
Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously
Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral
BTIG Research downgraded Athira Pharma from Buy to Neutral
Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G - Athira Pharma, Inc. (0001620463) (Subject)
SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i
BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D
New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"
Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto
JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price target.
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, an oral, small molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system in development for the treatment of amyotrophic lateral sclerosis (ALS).
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. "We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating drug candidate has improved blood-brain-barrier penetration and pharmacokinetic properties. Specifically, preclinically ATH-1105 has shown a consistent ability in various ALS models to reduce plasma neurofi
BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease (AD) will be presented at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) taking place October 29 - November 1, 2024, in Madrid, Spain. Presentation Details: Title: Fosgonimeton for the Treatment of Alzheimer's Disease; Efficacy and Safety Results from the LIFT-AD TrialSession: Oral Communications: OC2 Date/Time: Tuesday, October 29 at 5:10 p
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025 Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following the topline data readout from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to
On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across
BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors. Dr. Litton will also